Alladapt Immunotherapeutics, Inc.

We'd like to thank Healio for the opportunity to discuss how ADP101 addresses limitations in current oral immunotherapy treatments for #FoodAllergy and our recently presented Phase 1/2 Harmony data at #ACAAI23. Read the interview with our CEO Ashley Dombkowski below.

Thrilled to share that our CEO, Ashley Dombkowski, recently engaged in an insightful conversation with Abigail Beaney at Clinical Trials Arena about recent clinical data from our Phase 1/2 trial of ADP101, our innovative investigational oral immunotherapy which covers nine key food allergen groups. Learn more below. #MedicalInnovation #ClinicalTrials #PediatricHealth #FoodAllergies

Happy #Thanksgiving from our Alladapt family to yours!

Let's make this #Thanksgiving inclusive for everyone! Don't forget to ask your guests about #FoodAllergies to help ensure that everyone can safely enjoy a delicious meal. Check out more tips for accommodating allergies when you're holiday hosting in the article below.

More exciting news on the treatment front as Alladapt Immunotherapeutics, Inc. receives FDA Fast Track designation for its OIT treatment that tackles food allergies to all Top 9 at the same time.

We are proud to announce that ADP101 has received Fast Track designation from the FDA. This is an important milestone for people suffering from the substantial burden of #FoodAllergy, which requires constant, meticulous avoidance of all consumption or contact with allergens. We are excited to collaborate even more closely with the FDA as we move ahead to expedite development of this important therapy. Learn more in today's press release.

We're grateful for the opportunity to share promising clinical results with the food allergy community at the #ACAAI23 meeting in Anaheim! In case you missed it, read highlights from our Phase 1/2 Harmony Study evaluating ADP101 for the treatment of patients with mono- and multi- #FoodAllergy.

Exciting news in the fight against food allergies! Alladapt Immunotherapeutics, Inc. just shared groundbreaking results from their Harmony study at the ACAAI Annual Meeting. 🥳 ADP101, a multi-allergen oral immunotherapy, showed promising responses in pediatric patients, with 56% experiencing desensitization to multiple food allergies. This could be a game-changer for those seeking a broader and more effective treatment. 👩⚕️💊 #FoodAllergy

Tomorrow at #ACAAI23, we are excited to present data from our Phase 1/2 Harmony study demonstrating the therapeutic potential and safety of ADP101 for the treatment of #FoodAllergy. The Harmony data underscore the value of our multi-allergen approach and the potential for ADP101 to address a profound unmet need for patients and their families. Learn more in today's press release and join us during our presentation tomorrow.

We're presenting at the #ACAAI23 Annual Scientific Meeting next week and look forward to connecting with the #FoodAllergy community in Anaheim. Register at https://lnkd.in/dev2KbU and join us! American College of Allergy, Asthma and Immunology (ACAAI)